The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.
 
Yoshihiko Tomita
Honoraria - Astellas Oncology; Bristol-Myers Squibb; Ono Pharmaceutical; Pfizer; Sanofi
Consulting or Advisory Role - Novartis; Ono Pharmaceutical
Research Funding - Astellas Oncology (Inst); AstraZeneca; Ono Pharmaceutical (Inst); Pfizer; Takeda (Inst)
 
Sei Naito
No Relationships to Disclose
 
Naoto Sassa
No Relationships to Disclose
 
Atsushi Takahashi
No Relationships to Disclose
 
Tsunenori Kondo
Honoraria - Pfizer
 
Takuya Koie
No Relationships to Disclose
 
Wataru Obara
Honoraria - Astellas Oncology; Novartis; Pfizer
Research Funding - Astellas Oncology (Inst); Pfizer (Inst)
 
Yasuyuki Kobayashi
No Relationships to Disclose
 
Jun Teishima
No Relationships to Disclose
 
Masayuki Takahashi
No Relationships to Disclose
 
Hideyasu Matsuyama
Honoraria - Astellas Oncology; Pfizer
Research Funding - Astellas Oncology (Inst); Novartis (Inst); Pfizer (Inst)
 
Takeshi Ueda
Research Funding - Astellas Oncology (Inst)
 
Kenya Yamaguchi
No Relationships to Disclose
 
Takeshi Kishida
No Relationships to Disclose
 
Ryoichi Shiroki
Honoraria - Intuitive Surgical
Research Funding - Astellas Oncology (Inst)
 
Takashi Saika
Research Funding - Astellas Oncology (Inst)
 
Nobuo Shinohara
Honoraria - Astellas Oncology; Novartis; Pfizer
Research Funding - Astellas Oncology (Inst); Novartis (Inst); Pfizer (Inst)
 
Mototsugu Oya
Honoraria - Astellas Oncology; Novartis; Pfizer; Sanofi
 
Hiroomi Kanayama
Honoraria - Astellas Oncology; Novartis
Research Funding - Astellas Oncology (Inst)